781661-94-7 | 3-(2-methoxyethyl)-2-methyl-4,9-dioxo-1-(pyrazin-2-ylmethyl)naphtho[2,3-d]imidazol-1-ium bromide

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$10.00	$7.00
5mg	98%	in stock	$23.00	$17.00
10mg	98%	in stock	$35.00	$25.00
50mg	98%	in stock	$99.00	$69.00
100mg	98%	in stock	$167.00	$117.00

Description

• Catalog Number: AB48350
• Chemical Name: 3-(2-methoxyethyl)-2-methyl-4,9-dioxo-1-(pyrazin-2-ylmethyl)naphtho[2,3-d]imidazol-1-ium bromide
• CAS Number: 781661-94-7
• Molecular Formula: C20H19BrN4O3
• Molecular Weight: 443.2939
• MDL Number: MFCD11983133
• SMILES: COCCn1c(C)[n+](c2c1C(=O)c1ccccc1C2=O)Cc1cnccn1.[Br-]

Computed Properties

• Complexity: 571
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 28
• Hydrogen Bond Acceptor Count: 6
• Rotatable Bond Count: 5

Literature

• YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells.

  PloS one 20170101

• Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics.

  Molecular oncology 20140501

• Inhibition of pluripotent stem cell-derived teratoma formation by small molecules.

  Proceedings of the National Academy of Sciences of the United States of America 20130827

• Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab.

  The Journal of pharmacology and experimental therapeutics 20121001

• Survivin is a therapeutic target in Merkel cell carcinoma.

  Science translational medicine 20120509

• The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2.

  Anticancer research 20120501

• A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120401

• Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin.

  Molecular cancer therapeutics 20120101

• Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263.

  Biochemical pharmacology 20111101

• YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer.

  International journal of oncology 20110901

• Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110815

• YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.

  Anti-cancer drugs 20110601

• Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells.

  PloS one 20110101

• Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.

  British journal of cancer 20100629

• Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant.

  Drug metabolism and disposition: the biological fate of chemicals 20100101

• Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090601

• Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells.

  Drug metabolism and disposition: the biological fate of chemicals 20090301

• Survivin expression in primary malignant melanoma of the esophagus.

  Scandinavian journal of gastroenterology 20090101

• Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081110

• Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of YM155, a novel small-molecule survivin suppressant, in dog plasma.

  Biomedical chromatography : BMC 20080701